MedTrace Logo

Lithium and Acetate for Canavan Disease

NCT00657748 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-04-21

No results posted yet for this study

Summary

The aim of this study is to determine whether oral supplementation with lithium and acetate may improve the biological and clinical prognosis in patients with Canavan Disease.

Conditions

  • Canavan Disease
  • Infantile
  • Deficiency Disease
  • Aspartoacylase
  • Leukodystrophy, Spongiform

Interventions

DRUG

Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)

Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study

Sponsors & Collaborators

  • European Leukodystrophy Association

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Patrick Aubourg, MD, PhD · Assistance Publique - Hôpitaux de Paris

  • Caroline Sevin, MD, PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-09-30
Completion
2011-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00657748 on ClinicalTrials.gov